 The initial dose of BIO 300 will be administered on Day 1, Visit 2 in which safety data adverse events, electrocardiograms ECGs, results of safety laboratory determinations, pharmacokinetic PK and pharmacodynamic PD data will be collected. PK data will be collected from a minimum of six 6 study subjects from each cohort. PD data will be collected from all subjects in each study cohort. Day 1 of chemotherapy will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 1 day of BIO 300 dosing. BIO 300 will be administered in combination with the chemotherapy components of the protocol paclitaxel and carboplatin. During the first or second chemotherapy infusion, additional safety, PK and PD data will be collected. Day 1 of radiation therapy RT may be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. BIO 300 will continue to be administered daily; paclitaxel and carboplatin will be administered weekly and radiotherapy will be administered daily until a total dose of 60 Gy has been administered. During the period of combined BIO 300 and chemoradiotherapy 6 weeks, additional safety, PK and PD data will be collected weekly. An interim data analysis will be completed once the highest dose cohort concludes chemoradiation therapy, in an effort to determine the optimal biological dose. Following analysis, there will be an option to enroll up to an additional 12 subjects at the optimal biological dose. At the conclusion of the study, primary and secondary outcome measures will be evaluated. Data will be analyzed from all cohorts to determine the oncologic response, safety of BIO 300, and a recommended BIO 300 dose. 